Table 1.

Answers to survey questions stratified by continent.

Country	MTBDRplus/month	MTBDRplus use	MTBDRplus sample type	MTBDRsl/month	MTBDRsl use	MTBDRsl sample type	Other LPAs	Thermocycler manufacturer	Thermocycler	Ramp rate (°C/s)	Customisable ramp rate	Pre-screening Xpert MTB/RIF
Africa [14 laboratories; median (IQR) of 46 (20–241) MTBDR plus assays per month]
South Africa	900	Diagnosis	Smear-positive, smear-negative, isolates	50	Diagnosis	Smear-positive, smear-negative, isolates	N/A	Applied Biosystems	SimpliAmp	4.0	Yes	Yes
Swaziland	350	Diagnosis, research	Smear-positive, isolates	0	Diagnosis, research	Smear-positive, isolates	N/A	Applied Biosystems	2720 Thermal Cycler	2.7	No	Yes
South Africa	245	Diagnosis	Smear-positive, isolates	0	Diagnosis	Smear-positive, isolates	CM/AS	Applied Biosystems	ABI	4.0	Yes	Yes
Kenya	240	Diagnosis, research	Smear-positive, smear-negative	0	Research	Smear-positive	CM/AS	Applied Biosystems	GeneAmp 9700	2.3	Yes	Yes
South Africa	150	Diagnosis, research	Isolates	15	Diagnosis	Isolates	N/A	Applied Biosystems	ABI	6.0	Yes	Yes
Ethiopia	75	Diagnosis, research	Smear-positive, isolates	60	Diagnosis, research	Smear-positive, smear-negative, isolates	CM/AS	Applied Biosystems	2720 Thermal Cycler	2.7	No	Yes
South Africa	50	Diagnosis	Smear-positive, smear-negative, isolates	45	Diagnosis	Smear-positive, smear-negative, isolates	CM	Applied Biosystems	Proflex PCR system	4.0	Yes	No
Nigeria	42	Diagnosis, research	Smear-positive, smear-negative, isolates	27	Diagnosis, research	Smear-positive, smear-negative, isolates	CM/AS	Applied Biosystems	2720 Thermal Cycler	2.7	No	Yes
South Africa	40	Diagnosis, research	Isolates	0	Diagnosis, research	Isolates	CM	Applied Diagnosis	Various	4.0	Yes	Yes
Nigeria	25	Diagnosis	Smear-positive, smear-negative, isolates	35	Diagnosis	Smear-positive, smear-negative, isolates	CM	Hain Lifescience	GTQ-cycler 96	2.2	Yes	Yes
Cameroon	20	Diagnosis, research	Smear-positive, smear-negative	20	Diagnosis, research	Smear-positive, smear negative	CM/AS	Applied Biosystems	GeneAmp 9700	2.2	Yes	Yes
Botswana	20	Diagnosis, research	Smear-positive, isolates	20	Diagnosis, research	Smear-positive, isolates	CM	Hain Lifescience	GTQ-cycler 96	2.2	Yes	No
South Africa	20	Diagnosis, research	Smear-positive, smear-negative, isolates	0	Diagnosis, research	Smear-positive, smear-negative, isolates	CM	Bio-Rad	Various	4.0	No	No
Côte d’Ivoire	14	Diagnosis, research	Smear-positive, isolates	4	Diagnosis, research	Smear-positive, isolates	N/A	Applied Biosystems	2720 Thermal Cycler	2.7	No	Yes
Asia [7 laboratories; median (IQR) of 150 (15–256) MTBDR plus assays per month]
Azerbaijan	750	Diagnosis, research	Smear-positive, isolates	0	Diagnosis, research	Smear-positive, isolates	N/A	Unknown	Unknown	12.0	No	Yes
Kyrgyzstan	256	Diagnosis	Smear-positive, smear-negative, isolates	37	Diagnosis	Smear-positive	N/A	Biometra	Tprofessional	3.0	Yes	Yes
Bangladesh	150	Diagnosis	Smear-positive, smear-negative, isolates	120	Diagnosis	Smear-positive, smear-negative, isolates	N/A	Applied Biosystems	2720 Thermal Cycler	2.7	No	Yes
India	150	Diagnosis	Smear-positive, smear-negative, isolates	0	Diagnosis	Smear-positive, isolates	CM	Bio-Rad	Thermal Cycler T100	4.0	No	No
Pakistan	30	Diagnosis, research	Smear-positive, smear-negative, isolates	2	Research	Isolates	CM/AS	Hain Lifescience	GTQ-cycler 96	2.2	Yes	Yes
Myanmar	15	Diagnosis	Smear-positive, smear-negative, isolates	10	Diagnosis	Smear-positive, smear-negative, isolates	N/A	Applied Biosystems	2720 Thermal Cycler	2.7	No	Yes
Thailand	5	Diagnosis	Smear-positive, smear-negative	0	Research	Isolates	N/A	Applied Biosystems	2720 Thermal Cycler	2.7	No	No
Europe [10 laboratories; median (IQR) of 35 (23–64) MTBDR plus assays per month]
Denmark	90	Diagnosis, research	Smear-positive, smear-negative, isolates	5	Diagnosis, research	Smear-positive, isolates	CM/AS	Applied Biosystems	SimpliAmp	4.0	Yes	No
Belarus	75	Diagnosis	Smear-positive, smear-negative, isolates	80	Diagnosis	Smear-positive, smear-negative, isolates	CM/AS	Applied Biosystems	2720 Thermal Cycler	2.7	No	Yes
Moldova	60	Diagnosis, research	Smear-positive, smear-negative, isolates	24	Diagnosis, research	Smear-positive, smear-negative	N/A	Hain Lifescience	GTQ-cycler 96	2.2	Yes	Yes
Belgium	50	Diagnosis, research	Smear-positive, isolates	30	Diagnosis, research	Smear-positive, isolates	Nipro	Biometra	Tprofessional	3.0	Yes	Yes
Belarus	40	Diagnosis	Smear-positive, isolates	0	Diagnosis	Smear-positive, isolates	CM	Applied Biosystems	2720 Thermal Cycler	2.7	No	Yes
Germany	30	Diagnosis	Smear-positive, smear-negative, isolates	10	Diagnosis	Smear-positive, smear-negative, isolates	N/A	Hain Lifescience	GTQ-cycler 96	2.2	Yes	Yes
Denmark	25	Diagnosis, research	Smear-positive, smear-negative, isolates	4	Diagnosis, research	Smear-positive, smear-negative, isolates	CM/AS	Applied Biosystems	SimpliAmp	4.0	Yes	No
France	25	Diagnosis	Smear-positive, smear-negative, isolates	17	Diagnosis	Smear-positive, smear-negative, isolates	CM/AS, NTM-DR	Bio-Rad	Various	4.0	Yes	No
Italy	15	Diagnosis, isolates	Smear-positive, isolates	15	Diagnosis, research	Smear-positive, isolate	N/A	Hain Lifescience	GTQ-cycler 96	2.2	Yes	No
Spain	10	Diagnosis	Smear-positive, smear-negative, isolates	2	Diagnosis	Smear-positive, smear-negative, isolates	Inno-Lipa	Applied Biosystems	Various	4.0	Yes	No
South America (1 laboratory; 20 MTBDR plus assays per month)
Brazil	20	Diagnosis, research	Smear-positive, smear-negative, isolates	0	Diagnosis, research	Smear-positive, smear-negative, isolates	MOTT ID	Bio-Rad	C1000 Touch	5.0	Yes	Yes
Overall [32 laboratories; median (IQR) of 41 (20–150) MTBDR plus assays per month]
	3987			632		16/32 respondents test smear-negative specimens and are hence likely affected by incorrect ramp rate usage				7/32 used the correct ramp rate	20/32 have a customisable ramp rate	22/32 use Xpert as a pre-screen

LPA - Line probe assay; HCV – HCV Genotype 2.0 Assay (LiPA); CM-Genotype Mycobacterium CM Ver 2.0; NTM-DR – GenoType NTM-DR Ver 1.0;

AS - Genotype Mycobacterium AS Ver 1.0; IQR - Interquartile Range; Xpert – Xpert MTB/RIF assay.

Survey questions are in the supplement. Text in bold refers to laboratories using the manufacturer-recommended ramp rate.